Background
==========

The membrane proximal external region (MPER) of HIV-1 is an important target of broadly cross-reactive mAbs. CAPRISA participant, CAP206, developed anti-MPER antibodies early that became cross-neutralizing at 18 months post-infection. This coincided with neutralization of the C4 HIV-2/HIV-1 chimera containing the W670 residue, suggesting changes in an antibody paratope may have resulted in the acquisition of breadth. A neutralizing mAb (CAP206-CH12) was isolated, providing an opportunity to determine which somatic hypermutations contribute to breadth.

Methods
=======

The putative CAP206-CH12 reverted unmutated ancestor (RUA) was inferred using SoDA (<http://www.dulci.org>). Batch transient transfections were used to generate recombinant antibodies. Neutralization breadth and potency was tested against autologous, Tier 2, and HIV-2/HIV-1 MPER chimeric viruses using the TZM-bl assay. Binding to MPER peptides was assessed by ELISA and surface plasmon resonance (SPR).

Results
=======

CAP206-CH12_RUA bound the MPER.03 peptide with a Kd of 120nM, 15-fold weaker than CAP206-CH12 binding, but had no neutralizing activity. Since CAP206-CH12 and its RUA differed by 19 residues in the heavy chain and 9 in the light chain, we designed an intermediate precursor (IP) where changes near the CDRs in CAP206-CH12 were reverted back to the germline sequence (11 in the heavy and 5 in the light chain). This CAP206-CH12_IP did not neutralize the C4 chimera suggesting that changes responsible for the affinity-matured CAP206-CH12 neutralizing capacity were among these 16 residues. Chimeric pairs of the light chain IP with the heavy chain of CAP206-CH12 or CAP206-CH12_RUA showed binding to MPER with differences in binding kinetics.

Conclusion
==========

The reduced binding and neutralizing activity of CAP206-CH12_RUA and CAP206-CH12_IP compared to CAP206-CH12 suggests a correlation between affinity maturation, neutralization breadth and potency. Ongoing work will assess the affinity maturation of CAP206-CH12 by determining moieties in the antibody paratope associated with effective epitope recognition and the effects of somatic mutations on the evolution of neutralization.
